<DOC>
	<DOCNO>NCT00004186</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy treat patient small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose limit toxicity topotecan combine ifosfamide patient limited extensive stage small cell lung cancer . II . Determine pharmacokinetics topotecan correlate toxicity tumor response patient . III . Determine effect topotecan apoptosis tumor tissue correlate apoptosis-inducing effect antitumor effect topotecan patient . IV . Determine response rate , time progression , survival chemotherapy naive limited extensive stage small cell lung cancer patient treat ifosfamide topotecan crossover consolidation/salvage therapy carboplatin etoposide . V. Determine response rate , time progression , survival pretreated limited extensive stage small cell lung cancer patient treat ifosfamide topotecan salvage therapy . OUTLINE : This dose escalation study topotecan ( phase I ) . Patients stratified disease stage ( extensive v limit ) prior chemotherapy ( naive v pretreated ) phase II . Induction therapy : Patients receive topotecan IV 72 hour ifosfamide IV 30 minute every 3 week . Chemotherapy naive patient complete partial response 3 course , stable disease 2 course , progressive disease time receive consolidation/salvage chemotherapy . Pretreated patient continue induction regimen minimum 6 course unless disease progression unacceptable toxicity . Phase I : Cohorts 3-6 patient receive escalate dos topotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 6 patient experience dose limit toxicity . Salvage chemotherapy : Patients extensive stage disease receive carboplatin IV 30 minute day 1 etoposide IV 45 minute day 1 , 2 , 3 . Treatment repeat every 3 week 4 6 course . Patients limited stage disease undergoing chest irradiation receive treatment every 28 day first course . Patients follow every 2 month 1 year , every 3 month 1 year , every 4 month thereafter . PROJECTED ACCRUAL : Approximately 15-20 patient accrued phase I approximately 35 patient accrue phase II study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm limited extensive stage small cell lung cancer Measurable evaluable disease No uncontrolled brain metastasis PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL Renal : Creatinine great 1.5 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception No malignancy within past 5 year , except : Nonmelanomatous skin cancer Carcinoma situ cervix No significant active infection PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 1 prior first line chemotherapy regimen Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy ( except brain irradiation ) Surgery : Recovered recent surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>limited stage small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
</DOC>